NASDAQ: ADMS | Healthcare / Drugs - Generic / USA |
6.65 | +0.1600 | +2.47% | Vol 591 203 | 1Y Perf -30.22% |
Dec 13th, 2019 16:00 |
BID | 5.98 | ASK | 6.66 | ||
Open | 6.47 | Previous Close | 6.49 | ||
Pre-Market | - | After-Market | 6.66 | ||
- -% | 0.01 0.15% |
Target Price | 12.43 | Analyst Rating | Moderate Buy 2.30 | |
Potential % | 86.92 | Finscreener Ranking | ★★★+ — - | |
Insiders Trans % 3/6/12 mo. | -100/-100/-100 | Value Ranking | — - | |
Insiders Value % 3/6/12 mo. | -100/-100/-100 | Growth Ranking | ★★+ 46.10 | |
Insiders Shares Cnt. % 3/6/12 mo. | -100/-100/-100 | Income Ranking | — - | |
Market Cap (M) | 185 | Earnings Rating | Strong Sell | |
Price Range Ratio 52W % | 35.79 | Earnings Date | 7th Nov 2019 |
Today's Price Range 6.386.70 | 52W Range 3.3512.57 |
Summary:
Buy
Technical Indicators: | Neutral |
Moving Averages: | Strong Buy |
Performance | |||
---|---|---|---|
1 Week | 2.78% | ||
1 Month | 18.75% | ||
3 Months | 5.06% | ||
6 Months | 46.48% | ||
1 Year | -30.22% | ||
3 Years | -57.04% | ||
5 Years | -52.40% | ||
10 Years | - |
Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
Return on Equity (5Y Avg) | -60.38 | |||
ROE last 12 Months | -165.47 | |||
Return on Assets (5Y Avg) | -29.52 | |||
ROA last 12 Months | -50.73 | |||
Return on Capital (5Y Avg) | -36.89 | |||
ROC last 12 Months | -50.81 | |||
Return on invested Capital Q | -14.73 | |||
Return on invested Capital Y | -60.63 | |||
Assets Turnover | 0.10 | |||
Receivables Turnover | 6.00 |
Valuation | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
PE Ratio | - | |||
PB Ratio | 9.13 | |||
PS Ratio | 3.57 | |||
Price to Cash Flow | 23.20 | |||
Price to Free Cash Flow | -2.10 | |||
Cash Flow Per Share | -3.12 | |||
Price to Tangible Book | 9.13 | |||
Book Value per Share | 0.71 | |||
Enterprise Value (K) | 164 563 | |||
Forward PE | -2.61 | |||
PEG | - |
Financial Strength | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
Quick Ratio | 5.90 | |||
Current Ratio | 6.30 | |||
Long Term Debt to Total Capital | 0.87 | |||
Total Debt to Equity | 6.80 | |||
Interest Coverage | -6.30 | |||
Leverage Ratio | 3.90 |
Profitability | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
Gross Margin | 95.20 | |||
EBIT Margin | -185.70 | |||
EBITDA Margin | -183.10 | |||
Pre-tax Profit Margin | -5 965.50 | |||
Profit Margin | - |
Revenue | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
Revenue LTM (K) | 51 604 | |||
Revenue per Share | 1.85 | |||
Revenue Growth 3 Years | 348.39 | |||
Revenue Growth 5 Years | 4.18 |
Dividends | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
Dividend Yield | - | |||
Dividend Rate | - | |||
Dividend Growth 3 Years | - | |||
Dividend Growth 5 Years | - | |||
Payout ratio | - |
Earnings History | Estimate | Reported | Surprise % |
---|---|---|---|
Q03 2019 | -0.90 | -0.99 | -10.00 |
Q02 2019 | -0.98 | -0.90 | 8.16 |
Q01 2019 | -1.13 | -1.08 | 4.42 |
Q04 2018 | -1.36 | -1.06 | 22.06 |
Q03 2018 | -1.34 | -1.22 | 8.96 |
Q02 2018 | -1.41 | -1.26 | 10.64 |
Q01 2018 | -1.38 | -1.35 | 2.17 |
Q04 2017 | -1.15 | -1.27 | -10.43 |
Earnings Per End | Estimate | Revision % | Trend |
---|---|---|---|
12/2019 QR | -0.95 | -13.10 | Negative |
12/2019 FY | -3.91 | -4.55 | Negative |
3/2020 QR | -0.82 | -5.13 | Negative |
12/2020 FY | -2.47 | -3.35 | Negative |
Next Report Date | - |
Estimated EPS Next Report | -0.90 |
Estimates Count | 5 |
EPS Growth Next 5 Years % | - |
Volume Overview | |
---|---|
Volume | 591 203 |
Shares Outstanding (K) | 27 858 |
Trades Count | 3 897 |
Dollar Volume | 4 042 149 |
Avg. Volume | 483 262 |
Avg. Weekly Volume | 418 282 |
Avg. Monthly Volume | 413 981 |
Avg. Quarterly Volume | 576 427 |
Analyst Ratings | Current | 1 M ago | 3 M ago |
---|---|---|---|
Strong Buy | |||
Moderate Buy | |||
Hold | |||
Moderate Sell | |||
Strong Sell | |||
Rating | Moderate Buy | Moderate Buy | Moderate Buy |
Adamas Pharmaceuticals Inc discovers, develops, and sells therapies for chronic neurologic disorders. The company's approved/commercial product is GOCOVRI, an amantadine therapy for the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease. It operates in one reportable segment: the development and commercialization of therapeutics targeting chronic disorders of the central nervous system. The company generates its revenues primarily from the United States.
CEO: Gregory T. Went
Teplephone: +1 510 450-3500
Address: 1900 Powell Street, Emeryville 94608, CA, USA
Copyright (c) 2019. All rights reserved. Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate quotes are realtime. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.com, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
All rights reserved. Financial Market Data powered by Quotemedia.com. All rights reserved. View the Terms of Use. NYSE/NYSE MKT (AMEX) data delayed 20 minutes. NASDAQ and other data delayed 15 minutes unless otherwise indicated. Technology and data provided by TeleTrader. Conditions of Use. The regulations of the respective stock are to be observed. Copyright © 2019. All market data is provided by Barchart Solutions. Futures: at least a 10 minute delay. Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. To see all exchange delays and terms of use, please see disclaimer. The Cryptocurrency Market realtime data provided by Cryptocompare.com
Don´t have an account? Register